Trials
Search / Trial NCT06442852

Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease

Launched by JIAJIE CHEN · May 30, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between certain tiny molecules in the blood, called microRNAs (miRNAs), and the risk and severity of Alzheimer's Disease (AD). Researchers want to understand how changes in these miRNAs might be linked to the brain's ability to function, especially in relation to memory and learning. They will compare the levels of specific miRNAs in the blood of people with Alzheimer's to those in healthy volunteers. By doing this, they hope to find new ways to diagnose Alzheimer's early and understand how it affects the brain.

To participate in this study, individuals must either be diagnosed with Alzheimer's Disease or be healthy volunteers without any signs of memory issues. Alzheimer's patients need to meet specific criteria for diagnosis and have a certain level of cognitive decline, while healthy volunteers should have no cognitive complaints and score above a set threshold on a memory test. Participants can expect to provide blood samples and undergo evaluations to help researchers learn more about the disease. This study is currently recruiting participants of all ages, and understanding the role of miRNAs could lead to important advancements in diagnosing and treating Alzheimer's Disease.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Alzheimer's disease patients:
  • • Meet the diagnostic criteria of NINCDS-ADRDA for AD
  • • Clinical Dementia Scale (CDR) score ≥0.5
  • Healthy volunteers:
  • • No complaints or symptoms of cognitive impairment
  • • MMSE score is higher than the threshold value
  • Exclusion Criteria:
  • Alzheimer's disease patients:
  • • Dementia or cognitive impairment due to other diseases
  • • Combined with delirium
  • • A history of drug abuse
  • • Severe deafness, aphasia and other impact scale score
  • Healthy volunteers:
  • • had an organic brain lesion
  • • Suffering from other major physical diseases: such as severe immune diseases

Trial Officials

Kai Zheng

Principal Investigator

Tongji Hospital

About Jiajie Chen

Jiajie Chen is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial designs and rigorous methodologies. With a focus on collaboration and ethical practices, Jiajie Chen leads initiatives that span various therapeutic areas, ensuring the highest standards of safety and efficacy in clinical studies. The organization emphasizes transparency and communication with stakeholders, aiming to foster trust and enhance the overall clinical trial experience. Through its strategic partnerships and commitment to scientific excellence, Jiajie Chen plays a pivotal role in the development of new therapies and healthcare solutions.

Locations

Wuhan, Hubei, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0